Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novalar Pharmaceuticals Inc.

www.novalarpharm.com

Latest From Novalar Pharmaceuticals Inc.

China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences

Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.

BioPharmaceutical China

China’s Hengrui In-Licenses AMD Antibody Program From X-Body Biosciences

Hengrui becomes the first Chinese manufacturer to in-license an early stage MAb from a Western biopharma as it looks to develop an age-related macular degeneration therapy that could compete with Novartis/Roche’s Lucentis and Bayer/Regeneron’s Eylea.

BioPharmaceutical North America

Sanofi-Aventis and Novalar file OraVerse in certain EU countries

Sanofi-Aventis and Novalar Pharmaceuticals have filed OraVerse (phentolamine mesylate) for the reversal of local anaesthesia for the acceleration for normal sensation and function following routine dental procedures in the UK, Germany, Italy, France and Spain.

Neurology Spain

US paediatric panel to review adverse events for four proton pump inhibitors

The US FDA's paediatric advisory committee will meet on 21 June to discuss paediatric-focused safety reviews for 13 drugs, including four proton pump inhibitors.

Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Drug Delivery
      • Site Specific
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Dental & Oral Products
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Novalar Pharmaceuticals Inc.
  • Senior Management
  • Donna Janson, Pres. & CEO
    Jaime Nassar, VP, Mktg.
    Doug Bakan, PhD, VP, Product Dev.
  • Contact Info
  • Novalar Pharmaceuticals Inc.
    Phone: (858) 436-1100
    12555 High Bluff Dr., Ste. 300
    San Diego, CA 92130
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register